News for AGTC Stock

Beacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025 Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation *FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER* *REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER* Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022 Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022 Syncona Commences Tender Offer for All Outstanding Shares of Applied Genetic Technologies Corporation Syncona to Acquire Applied Genetic Technologies Corporation AGTC to Participate in Upcoming Investor Conferences AGTC to Participate in Upcoming Investor Conferences AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility AGTC Announces Pricing of $10 Million Underwritten Public Offering AGTC Announces Proposed Underwritten Public Offering AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer AGTC Announces Key Appointments to Leadership Team AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board AGTC to Present at the H.C. Wainwright Global Investment Conference AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa AGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building’s Structural Completion Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy AGTC to Present at Cell & Gene Meeting on the Mediterranean AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting AGTC Announces Pricing of Public Offering of Common Stock AGTC Announces Proposed Public Offering of Common Stock AGTC to Participate in Upcoming Investor Conferences AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021 AGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 Achromatopsia AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022 AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP) AGTC to Participate in the H.C. Wainwright BioConnect 2022 Conference AGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of Directors AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer AGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual Meeting AGTC Appoints Hope D’Oyley-Gay as General Counsel AGTC to Participate in the Stifel 2021 Virtual Healthcare Conference AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021 AGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021 AGTC to Present at Upcoming Dry AMD Therapeutic Development Summit AGTC Announces Two Key Leadership Team Appointments AGTC to Present at Upcoming Cell & Gene Meeting on the Mesa AGTC to Present at Upcoming Cell & Gene Management Meeting on the Mesa AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021 AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021 AGTC to Participate in Clinical Trials in Rare Diseases Conference Panel and Case Study AGTC is Excited to Announce Seasoned Healthcare Financial and Operations Executive Jonathan I. Lieber as their new Chief Financial Officer AGTC to Present at the H.C. Wainwright 23rd Annual Global Investment Conference AGTC to Present at the 2021 Wells Fargo Virtual Healthcare Conference Greater Gift, AGTC, and 2020 On-site Partner To Honor & Celebrate Clinical Trial Participants and Provide Eye Exams to Underserved Children in the Local Community AGTC Announces Sponsorship of Achroma Corp’s No Roadblocks Program AGTC Appoints Ophthalmology and Retinal Disease Specialist and Industry R&D Veteran Yehia Hashad, MD to its Board of Directors AGTC to Participate in Envision Virtual Conference East 2021 Panel Discussion AGTC to Participate at Upcoming Investor Conferences AGTC to Host Virtual R&D Day on July 22, 2021 AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials AGTC to Present at American Optometric Association’s Optometry’s Meeting   AGTC Expands Leadership Team with Appointment of Key Regulatory Leader AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021 Concept Companies Breaks Ground on Expansion for AGTC in Alachua's Foundation Park AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 17, 2021 AGTC Reports Process Development Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting AGTC Announces Departure of Chief Scientific Officer AGTC licenses Promoter Technology to SparingVision SAS TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials AGTC to Present at the Gene Therapy Patient Engagement Summit, Held Virtually, March 24, 2021 AGTC to Present at Upcoming Investor Conferences AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021 AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021 AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020 AGTC Executives Awarded First Place in the BioProcess International Reader’s Choice Awards, Cell & Gene Therapies Category AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021 AGTC Announces Pricing of Public Offering of Common Stock and Warrants AGTC Announces Proposed Public Offering of Common Stock and Warrants AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2020 AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms AGTC to Present at Upcoming Virtual Conferences AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator AGTC to Participate at Upcoming Virtual Investor Conferences AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Program AGTC Formalizes Patient Advisory Council to Provide Insights and Guidance on Patient Perspectives for Pipeline Therapies AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2020 AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process AGTC Announces Publication of Positive Preclinical Data that Provides Foundational Scientific Evidence for its Ongoing Clinical Program in Patients with X-Linked Retinitis Pigmentosa (XLRP) AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 13, 2020 AGTC Set to Join Russell 3000® and 2000® Indexes AGTC to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference on June 23, 2020